**Long-Acting Technologies Community Advisory Board (LAT CAB)**

**2021–2026 Term**

**Background**

The Unitaid funded [LONGEVITY](https://www.liverpool.ac.uk/centre-of-excellence-for-long-acting-therapeutics/longevity/) and [GLAD](https://depts.washington.edu/tlcart/tlc-art-glad-project-covered-at-laii-2020/) projects aim to develop novel, long-acting therapeutics, and preventives for malaria, hepatitis C virus (HCV), HIV and latent tuberculosis infection (LTBI). [Treatment Action Group (TAG)](https://www.treatmentactiongroup.org/) is coordinating the community engagement aspects and developing treatment literacy materials about long-acting therapeutics and preventives. TAG in collaboration with [Afrocab Treatment Access Partnership](http://www.afrocab.info/) are coordinating a long-acting technologies (LAT) community advisory board (CAB), and invite applications from strong, research-literate treatment activists and community leaders in high-burden malaria, HCV, HIV and TB countries and from affected communities and networks.

LAT CAB members do not have to be experts in the science but must have a strong interest in gaining scientific knowledge by: engaging with malaria, HCV, HIV and TB research scientists and product sponsors to become community experts in research and development (R&D) for long-acting therapeutics and preventives; promoting access to the benefits of these LATs research; and contributing to study and trial design, review, and other processes involved in access to these new drugs.

**Objectives**

* Manage a dedicated CAB comprised of treatment activists and community leaders to review the state of treatment research, contribute to research protocols including those related to product acceptability, and engage in the R&D process, including advising on research questions and trial design for long-acting technologies for HCV cure, HIV treatment, and preventives for malaria and latent TB infection (LTBI);
* Strengthen research and scientific literacy among treatment activists and community leaders, in partnership with technical experts to analyze and review protocols, surveys and other research materials at learning sessions and workshops;
* Engage with clinical researchers, drug developers, contract manufacturing organization(s), and project partners on the scientific, cost/pricing, and access plans for high-, middle-, and low-income countries; and
* Prepare communities, and advise on approaches, for the introduction of LATs, which may include the development of community recommendations on the R&D.

**Membership Requirements for 2021–2026 Term**

* Interest in HCV, HIV, malaria, and TB science and in gaining scientific research literacy;
* Basic knowledge in one or more of the disease areas: HCV, HIV, malaria, and TB;
* Treatment activism or health advocacy experience, plus connection to community and/or civil society networks at local, national and regional/global levels;
* Ability to disseminate information, follow through on tasks and engagements, and bring local, national, regional and/or global perspectives to discussions;
* Ability to confidently communicate in English (the LAT CAB working language);
* Capacity to actively participate in bi-/monthly (every 2 months) virtual meetings and regularly communicate via email (approximately 5 hours/2 months);
* Availability to participate in in-person meetings (costs covered by TAG, when possible);
* Access to internet and Dropbox.

**Expectations**

* The LAT CAB expects members to commit to the full tenure, i.e. 2021-2026, or the duration of the LONGEVITY and GLAD Projects.
* The LAT CAB meets once every 2 months, unless otherwise communicated, until the clinical trials protocols are developed, in which case it could meet more frequently to analyze research protocols, surveys, and other materials. If task-based, smaller working groups (WG) are formed, WG members would decide on the meeting frequency of the WG needed to accomplish the task (e.g., prepare a presentation, statement, etc.).
* LAT CAB members can expect to commit to an average of 5 hours per/2 months (which would include 2 hour meetings, plus about 3 hours for readings, meeting preparation, and review of materials).
* CAB members may be expected to travel to participate in CAB meetings and other events.
* **CAB members who miss more than two (2) meetings in a calendar year--or more than one (1) meeting in a six-month period--without advance notice or substantiated explanations would be asked to reassess their commitment and participation, and future communications support/stipend will be under review or withheld. Whether** **to recruit a new member or expand the CAB would be decided on by majority rule.**

The LAT CAB representation strives for diversity in geographic region, gender, experience, and disease expertise. Individuals from the global South, high-burden countries, all communities affected by malaria, HIV, HCV, and TB, and from key populations, including people who inject or use drugs, are especially encouraged to actively participate and bring their perspectives. The LAT CAB includes anyone irrespective of HIV or other health status, religion, gender, sexual orientation or lifestyle.

**CAB Members are not paid**, but we work with members to ensure their participation is cost-neutral by providing communication support and covering related travel costs. LAT CAB members serve in their individual, capacity and do not represent any organization.

I acknowledge and accept the terms regarding the expectations and requirements for becoming a LAT CAB member.

Name

Signature

Date